Home・Listă Acțiuni・Neurocrine Biosciences Inc

Neurocrine Biosciences Inc

Deschisă

SectorSănătate

152.22 1.28

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

148.4

Maxim

153.31

Indicatori cheie
By Trading Economics
Venit	-54M 144M
Vânzări	145M 959M
P/E Medie Sector	23.867 57.002
EPS	2.36
Marjă de profit	15.057
Angajați	2,500
EBITDA	-64M 190M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+39.5% upside

Dividende
By Acuity
Următoarele câștiguri	27 oct. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-974M 17B
Deschiderea anterioară	150.94
Închiderea anterioară	152.22

Sentimentul știrilor

By Acuity

50%

171 / 340 Clasament în Healthcare

Neurocrine Biosciences Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 aug. 2026, 20:02 UTC

News

Event

Neurocrine Biosciences shares decline as Morgan Stanley lowers price target to $182, citing safety concerns over VYKAT XR and reports of serious adverse events.

12 aug. 2026, 21:11 UTC

Event

Neurocrine Biosciences published positive KINECT-PRO™ study results, yet shares are lower in after-market hours, continuing a trend of declining daily closes.

10 aug. 2026, 19:36 UTC

Event

Neurocrine Biosciences initiates a Phase 1 study for NBIP-'1968, contributing to a rise in shares during the session. The stock remains below its 20-day moving average.

7 aug. 2026, 19:46 UTC

News

Event

Social Media

Neurocrine Biosciences initiates a Phase 1 study for NBIP-'1968, a GLP-1/GIP/glucagon receptor triple agonist for obesity, boosting shares during Friday's session.

6 aug. 2026, 19:36 UTC

Neurocrine Biosciences Inc shares are lower during Thursday's session, continuing a decline since Wednesday's close, with no specific news identified.

5 aug. 2026, 23:46 UTC

Neurocrine Biosciences Inc shares are higher in after-market trading, buoyed by investor interest despite disappointing private sector employment data.

4 aug. 2026, 19:26 UTC

News

Wedbush raised its price target on Neurocrine Biosciences to $194, while Canaccord Genuity increased its target to $210. Shares are trading roughly flat.

3 aug. 2026, 20:51 UTC

Neurocrine Biosciences Inc shares are higher in after-market trading, reflecting a positive trend in the biotechnology sector amid broader market gains.

31 iul. 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

30 iul. 2026, 21:51 UTC

News

Neurocrine Biosciences reported second-quarter revenues of $959 million and raised 2026 INGREZZA sales guidance, with shares trading higher in after-market hours.

29 iul. 2026, 18:46 UTC

Neurocrine Biosciences Inc shares are trading lower today with no specific news identified. The stock fluctuated earlier in the session amid broader market activity.

28 iul. 2026, 23:41 UTC

Neurocrine Biosciences Inc shares are higher in after-market hours, rebounding from an earlier dip and maintaining a position above the 20-day moving average.

27 iul. 2026, 19:21 UTC

Social Media

Neurocrine Biosciences shares are higher as Cantor Schimmer ranks it among top picks, citing undervaluation and expected advancements in its portfolio.

24 iul. 2026, 20:07 UTC

Neurocrine Biosciences Inc shares are higher today, despite an earlier pullback. Broader market sentiment is influenced by falling oil prices easing inflation concerns.

22 iul. 2026, 19:51 UTC

News

Neurocrine Biosciences Inc. appointed Samir Siddhanti as Chief Business Officer. Despite this leadership change, shares are trading lower amid cautious investor sentiment.

21 iul. 2026, 19:51 UTC

News

Neurocrine shares rise after Guggenheim raises price target to $200.

20 iul. 2026, 23:46 UTC

Neurocrine Biosciences Inc is trading higher in after-market hours, maintaining a strong performance above its 20-day moving average and near its one-month range.

Comparație

Modificare preț

Neurocrine Biosciences Inc Așteptări

Obiectiv de preț

By TipRanks

39.5% sus

Prognoză pe 12 luni

Medie 210.4 USD 39.5%

Maxim 249 USD

Minim 165 USD

În baza a 26 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNeurocrine Biosciences Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

26 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 26 analiști care au acordat evaluări ale acțiunilor Neurocrine Biosciences Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

171 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.